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Bicalutamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-
-hydroxy-2-methylpropanamide, is a nonsteroidal antiandrogen mainly used for the treat-
ment of prostate cancer (1) and is orally active (Fig. 1). It has the ability to competitively
block the growth-stimulating effects of androgens on prostate cancer (2). Though bica-
lutamide has become popular for the treatment of prostate cancer, it has certain demerits
such as high lipophilicity and poor aqueous solubility (3). Drugs with poor aqueous solu-
bility generally show variable absorption (4). The low aqueous solubility of bicaluta-
mide may be due to its polymorphism and hence the drug has been classified as a BCS
class II (low solubility and high permeability) drug according to the biopharmaceutical
classification system (5). The very low solubility of bicalutamide accounts for dissolu-
tion as its rate determining step for bioavailability. Improved dissolution rate can be ex-
pected to increase oral bioavailability of the drug, resulting in reduction of dosing fre-
quency and improved patient compliance (6).
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Liquid antisolvent process was explored as a solubility
modulating tool. Bicalutamide, a poorly water soluble
drug, was used as a candidate. Low aqueous solubility
and poor dissolution of bicalutamide results into poor
and variable bioavailability. Therefore, the objective of the
present work was to modify the solubility of bicalutami-
de using the liquid antisolvent precipitation process.
HPMC E5 and Poloxamer 407 were shortlisted as a hy-
drophilic polymer and surfactant, respectively, for the pro-
cess. Process optimization was done with respect to the
hydrophilic polymer, surfactant and drug loading concen-
tration. The resultant microcrystals were characterized
with various instrumental techniques for material char-
acterization such as IR, DSC, SEM, XRD, particle size, spe-
cific surface area and dissolution kinetics.
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Numerous approaches have been reported in literature for solubility enhancement;
they include particle size reduction (7), surfactant incorporation (8), inclusion comple-
xation (9), microencapsulation (10), solid solutions (11) and prodrug formulation (12).
This work was aimed to investigate the solubility enhancement of bicalutamide us-
ing liquid antisolvent precipitation process (LASPP) and subsequently to improve its dis-
solution profile. Liquid antisolvent precipitation process basically involves precipitation
of a solid solute previously dissolved in an organic solvent by adding it into a non-sol-
vent (antisolvent) under stirring. The process is preferably carried out in the presence of
some steric and electrostatic stabilizers such as hydrophilic polymers and/or surfactants.
During precipitation, these hydrophilic polymers and surfactants help in increasing the




Raw bicalutamide was obtained from Hetero drugs, India. Hydroxypropyl methyl-
cellulose (HPMC E5) was provided by Colorcon, India. Polyvinyl pyrrolidone vinyl ace-
tate copolymerisate K28 (Kollidon VA64), ethylene oxide propylene oxide block copo-
lymer (Poloxamer 407), polyvinylpyrrolidone K90 (PVPK90), polyoxyethylene glycerol
triricinoleat 35 (Cremophor EL) and macrogol 15 hydroxy stearate (Solutol HS 15) were
kindly donated by BASF Co., Germany. Polyvinylalcohol (PVA, Mr 31,000–50,000) was a
gift from Nippon (Japan), labrasol was a gift from Gattefosse (France), polyoxy ethylene
(20) sorbitan monolaurate (Tween 20), polyoxy ethylene (80) sorbitan monolaurate (Tw-
een 80) were purchased from Merck (India). Acetone and sodium lauryl sulphate (SLS)
was purchased from S. D. Fine Chemicals (India). Aerosil 200 was obtained from Degu-
ssa (Germany). Sodium starch glycolate was procured from Roquette (France), and mi-
crocrystalline cellulose 102 (MCC) was obtained from FMC Biopolymers (Ireland).
Preparation of microcrystal particles
Bicalutamide microcrystal particles were prepared using an antisolvent precipitation
process. Bicalutamide 90 mg was completely dissolved in 1 mL of acetone. The prepared
drug solution was added dropwise into 20 mL water containing 0.3 % (m/V) of each poly-
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Fig. 1. Structure of bicalutamide.
mer and surfactant under stirring at 3000 rpm. Precipitation of drug particles occurred
immediately upon mixing and formed a suspension with a milky appearance. The sus-
pension was centrifuged at 10000 rpm for 10 min a (centrifuge Eltek TC4100 D, India)
and washed twice with 50 mL distilled water. The obtained particles were oven-dried at
60 °C overnight.
Formulation of LASPP microcrystals into tablets
Bicalutamide and LASPP microcrystals of bicalutamide were incorporated in tablets
with the composition given in Table I.
Tablets were compressed on a single station tablet compression machine (Cadmach,
India), using the 8-mm standard concave punch with a crushing strength of 7 to 9 kg cm–2.
The tablets so formed were used for the dissolution tests.
Tablet dissolution studies
Dissolution studies were performed following the USP apparatus 2 (paddle) method
(13). The paddle rotation and bath temperature were set at 50 rpm and 37.5 ± 0.5 °C, re-
spectively. Each test was carried out in 1000 mL of 1 % SLS dissolution medium for the
sink condition. Bicalutamide tablets (prepared as shown in Table I) containing 50 mg raw
or LASPP bicalutamide microcrystals were placed in the dissolution medium. Then,
10-mL aliquot samples were withdrawn at specified time intervals and were filtered us-
ing 0.45-mm polytetrafluoroethylene (PTFE) syringe filters. At each sampling time, an equ-
al volume of the test medium was replenished. The filtrate was diluted ten times with
the dissolution medium and quantified by UV spectrophotometric analysis at 273 nm.
Particle size measurement and specific surface area analysis
Particle size and distribution with a specific surface area of samples were determi-
ned by dynamic light scattering using a laser diffractometer (Mastersizer 2000, Malvern
Instruments, UK). The LASPP bicalutamide microcrystals were dispersed in distilled
water. Each measurement was performed in triplicate (Table II).
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Table I. Composition of tablets prepared for the dissolution study
Ingredient mg per tab
Bicalutamide / LASPP microcrystals 50
MCC 102 138
Sodium starch glycolate 10
Aerosil 200 2
MCC – microcrystalline cellulose
Scanning electron microscopy (SEM)
Morphology of the particles was observed using a scanning electron microscope
(SEM; JSM-6380LA, Jeol, Japan). LASPP bicalutamide microcrystals samples were coated
with gold and palladium using a vacuum evaporator and were examined using SEM at
15 kV accelerating voltage.
Fourier transform infrared spectroscopy
FT-IR spectroscopy was conducted on a FT-IR spectrometer (Spectrum 100, Perkin
Elmer, USA) using the attenuated total reflectance (ATR) method. Samples were well mixed
with KBr powder and kept in a sample holder. The scanning range was 450–4000 cm–1
and the resolution was 4 cm–1. A total of 32 reference scans were performed.
Thermal analysis
DSC measurements were carried out in an instrument Pyris 6 DSC (Perkin Elmer).
LASPP bicalutamide samples of 5 mg were accurately weighed and sealed in an alumi-
nium pan. The measurements were performed under a nitrogen purge flow rate of 20
mL min–1 at 20–240 °C at a heating rate of 10 °C min–1. An empty pan was used as refer-
ence and for calibration prior to each experiment.
Powder X-ray diffraction analysis
The XRPD patterns of bicalutamide samples were recorded in a Rigaku powder
X-ray diffraction system (Miniflex, Japan) with Cu-Ka radiation. The samples were run
over the most informative range from 0° to 60° of 2q. The step scan mode was performed
with a step size of 0.02° at a rate of 2° min–1.
RESULTS AND DISCUSSION
In this study, bicalutamide microcrystals were prepared using the liquid antisolvent
precipitation process in the presence of a hydrophilic polymer and amphiphilic surfac-
tant for the enhancement of the dissolution rate. Furthermore, the effective hydrophilic
polymers and surfactants used were screened for their ability to produce a smaller parti-
cle size, and particles having more wettability, thereby resulting in enhanced dissolution
rate. Raw bicalutamide and LASPP microcrystals were characterized in the solid state
using several analytical techniques such as dynamic light scattering, scanning electronic
microscopy, Fourier transformation-infrared spectroscopy, differential scanning calorim-
etry, powder X-ray diffraction analysis and dissolution test.
Selection of hydrophilic polymer
Screening was performed among different hydrophilic polymers including PVP K90,
PVA 31000–50000, Kollidon VA64 and HPMC E5 in distilled water (0.2 %, m/V) at a con-
stant drug concentration (90 mg mL–1). The microcrystals so formed were dried and in-
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corporated into tablets. Fig. 2a shows the dissolution profile of the different LASPP tab-
lets; HPMC E5 was found most suitable for carrying out further LASPP optimization.
Polymer concentration optimization
Liquid antisolvent process was carried out by varying the concentration of HPMC
E5. Fig. 2b shows the effect of HPMC E5 concentration on the dissolution rate of bicalu-
tamide. Increase in HPMC E5 concentration from 0 to 0.3 % (m/m) resulted in gradual
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Fig. 2. Dissolution profile of LASPP bicalutamide/bicalutamide affected by: a) polymers; b) HPMC
E5 concentration; c) Polaxamer 407 concentration (mean ± SD, n = 3).
increase in dissolution but beyond 0.3 % (m/m) the dissolution gradually decreased. This
could be due to the strong hydrophilic environment produced by the polymer, which al-
lowed spontaneous displacement of the bicalutamide particles in solution leading to an
increase in particle size.
Screening and optimization of surfactants
Different surfactants (0.2 %, m/m, in water) were tried, keeping HPMC E5 (0.3 %,
m/m, in water) and the drug (90 mg mL–1 of acetone) at constant concentration to check
their suitability for the LASPP bicalutamide crystals production. Fig. 3 shows the effect
of various surfactants on dissolution of bicalutamide in 10 and 45 min.
Fig. 2c shows the effectiveness of Poloxamer 407 for increasing the solubility of bi-
calutamide. The micellar regions of surfactants may be responsible for the provision of
in-process nucleation of bicalutamide microcrystals, which in turn cause a controlled par-
ticle size decrease, subsequently leading to an increased surface area and increased dis-
solution (14). Concentration of Poloxamer 407 was varied (0.2, 0.3 and 0.4 %, m/m, but
keeping HPMC E5 (0.3 %, m/m) constant. Fig. 2c shows the dissolution of LASP bicalu-
tamide microcrystals.
Effect of drug loading
Increase in drug concentration above 90 mg mL–1 increased the particle size. This
could be due to an increase in viscosity which can prevent diffusion between solution
and antisolvent and has been shown to result in non-uniform supersaturation and parti-
cle agglomeration (15).
Morphology and particle size distribution
SEM images of raw bicalutamide and LASPP bicalutamide microcrystal particles are
shown in Fig. 4. The LASPP bicalutamide microcrystals appear uniform and spherical,
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Cremophor EL Solutol HS 15 Labrasol Poloxamer 407 Tween 80 Tween 20
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Fig. 3. Effect of various surfactants on the dissolution of LASPP bicalutamide (mean ± SD, n = 3).
while the raw bicalutamide appears needle-like with regularly shaped crystals, which
are agglomerated and are of several microns in size.
Results from Table II show that addition of polymer and surfactant in aqueous
phase had an effect on particle size reduction and thereby increased the surface area,
when no polymer/surfactant was used in the process, the formation of granular struc-
tures took place.
DSC analysis and XRPD
The changes in polymorphism and crystallinity of bicalutamide before and after the
antisolvent precipitation process were assessed by comparing the DSC thermograms
(Fig. 5) and PXRD patterns (Fig. 6) of plain and LASPP bicalutamide microcrystals.
The DSC thermograms of raw bicalutamide and LASPP bicalutamide microcrystals
(Fig. 5) show a peak at 194–197 °C, which corresponds to the melting point of bicalu-
tamide. As shown in Fig. 5, the enthalpy of LASPP bicalutamide micrystals was lower
compared to that of raw bicalutamide, indicating decreased crystallinity for crystal par-
ticles obtained in the presence of polymer and surfactant. Also, there is an exothermic
peak at 155 °C for LASPP bicalutamide microcrystals, which may be due to the recrysta-
llization upon heating the drug. This additionally demonstrates the reduced crystallinity
of LASPP bicalutamide microcrystals compared to raw bicalutamide (7).
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Fig. 4. SEM images of: a) raw bicalutamide, and b) LASPP bicalutamide microcrystals.







Raw bicalutamide 143.26 5.440 0.802
LASPP microcrystal bicalutamide 23.956 2.667 1.52
a Span = (d90–d10)/d50
Fig. 6 shows that both raw bicalutamide and LASPP bicalutamide microcrystals had
the same polymorph with similar peak positions in the XRPD patterns. However, there
were some differences between the two samples in relative integrated intensities of each
peak. Percent crystallinity of raw bicalutamide and LASPP bicalutamide microcrystals
was found to be 30.15 and 25.25, respectively.
FTIR analysis
Fig. 7 shows FTIR spectra of raw bicalutamide and LASPP bicalutamide. Both are
characterized by sulphate (1517 cm–1), hydroxyl group (3581 cm–1), carbonyl (1689 cm–1),
NH (3338 cm–1) and nitrile (2230 cm–1). The identical FTIR spectra of raw bicalutamide
and LASPP bicalutamide suggested that there was no change in bicalutamide molecular
structure.
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Fig. 5. DSC of: a) raw bicalutamide,
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Fig. 6. XRPD of: a) raw bicaluta-
mide, and b) LASPP bicalutamide
crystals.
443





































































0 10 20 30 40 50
Time (min)
Fig. 8. Dissolution profile of raw bicalutamide tablets (), and LASPP bicalutamide microcrystals
tablets () (mean ± SD, n = 3).
Dissolution test
The test was performed as per FDA dissolution database guidelines and as reported
in the literature. The results are shown in Fig. 8. The dissolution rate enhancement for
LASPP bicalutamide tablets may be due to decrease in drug crystallinity.
CONCLUSIONS
In this study, microcrystal line particles of bicalutamide were prepared using a liq-
uid antisolvent precipitation technique. The results illustrate that the antisolvent precipi-
tation technique, in mild conditions, allows to prepare bicalutamide microcrystals with a
reduced particle size and enhanced dissolution properties. In the process, HPMC E5 and
Poloxamer 407 in aqueous phase were employed as a hydrophilic polymer and a sur-
factant, respectively, to inhibit crystal growth and aggregation, resulting in the forma-
tion of bicalutamide microcrystals. Dissolution rate was affected by the type of polymer
or surfactant used and the concentration of either the polymer or the drug. The dissolu-
tion properties of the processed bicalutamide microcrystal particles were enhanced in
comparison with those of the unprocessed drug by increasing the surface area caused by
a reduction in particle size and a decrease in crystallinity. This process can be used in a
cost effective manner for the production of immediate release formulations.
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S A @ E T A K
Teku}inski antisolvent postupak talo`enja za modifikaciju topljivosti bikalutamida
TARIQUE ALI MEER, KIRAN P. SAWANT i PURNIMA D. AMIN
Teku}inski antisolvent postupak upotrijebljen je za moduliranje topljivosti bikaluta-
mida. Zbog vrlo slabe topljivosti u vodi i sporog osloba|anja, bioraspolo`ivost bikaluta-
mida je mala i varijabilna. Cilj rada je pobolj{ati topljivost bikalutamida koriste}i anti-
solvent precipitaciju. Kao hidrofilni polimer kori{ten je HPMC E5, a kao surfaktant Polo-
xamer 407. Variranjem koli~ine polimera, surfaktanta i lijeka proces je optimiran. Nastali
mikrokristali analizirani su uobi~ajenim instrumentalnim tehnikama za karakterizaciju
materijala kao {to su IR, DSC, SEM, XRD, veli~ina ~estica, specifi~na povr{ina i brzina
osloba|anja.
Klju~ne rije~i: bikalutamid, pove}anje topljivosti, osloba|anje, teku}inska antisolvent precipitacija
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